Genetic variations in cytochrome P450 2C9 (CYP2C9) contribute to interindividual variability in the metabolism of clinically used drugs such as warfarin and tolbutamide. We functionally ...

Genetic variants of the enzyme that metabolizes warfarin, cytochrome P-450 2C9 (CYP2C9), and of a key pharmacologic target of warfarin, vitamin K epoxide reductase (VKORC1), contribute to ...

Because of the large difference in the dose required for warfarin, the anticoagulation effect must to be monitored regularly. Anticoagulation status is measured as the International Normalized ...

Seattle, WA - Researchers in Seattle say they have uncovered specific genetic variations that influence how people respond to warfarin dose. Their study suggests that haplotypes of the VKORC1 gene ...

“Our findings support rivaroxaban as a viable alternative to warfarin, offering predictable dosing and eliminating the need for routine monitoring in patients with post-MI left ventricular ...